Copenhagen - May 7, 2020 - The Board of Directors and the CEO of 2cureX AB ("2cureX") hereby publish the annual report for the fiscal year 2019. The annual report and associated audit report are available as an attached file and on the company's website (www.2curex.com).
On May 28, 2020 at 15:00 the Annual report will be presented for approval at the Annual General Meeting.
On May 29, 2020 at 10:00 (CET) the Annual report will be presented at a live webcast by CEO Ole Thastrup and CFO Carit J. Andersen.
Click here (http://www.2curex.com/live-event-2020-05-29-annual-report/) to access the public webcast.
For more information about 2cureX:
Ole Thastrup, Chief Executive Officer
E-mail: ot@2curex.com
Telephone: +45 2211 5399
www.2curex.com (https://www.2curex.com/2curex-is-accelerating-the-commercialization-of-inditreat-by-signing-two-distributor-agreements-to-prepare-for-launch-in-second-half-of-2020/www.2curex.com)
Certified Adviser
Svensk Kapitalmarknadsgranskning AB
Email: ca@skmg.se
Phone: +46 11 32 30 732
--
About 2cureX
2cureX has developed the IndiTreat® (Individual Treatment) test. IndiTreat® establishes thousands of 3D micro-tumors that are similar to the patient's tumor and identifies the treatment that most effectively kills the patient's tumor. Immediately after the test, the patient can be offered the selected treatment.
IndiTreat® is being clinically validated in clinical studies in colorectal cancer, ovarian cancer, pancreatic cancer and preventive cancer medicine. The clinical programs are conducted at major cancer hospitals in Denmark, Germany and United Kingdom.
IndiTreat® is presently being introduced into the European market through an Early Access Program.
The aspiration is that IndiTreat® becomes a standard tool in Precision Medicine for cancer patients.
The company is listed at the Nasdaq First North Growth Market in Stockholm (symbol "2CUREX").